Your browser doesn't support javascript.
loading
Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D2 /D3 Receptor Antagonist: A Phase 1 Randomized, Placebo-Controlled Single- and Multiple-Dose Escalation Study in Healthy Participants.
Whiting, Roger L; Darpo, Borje; Chen, Chunlin; Fletcher, Margaret; Combs, Dan; Xue, Hongqi; Stoltz, Randall R.
Afiliação
  • Whiting RL; Altos Therapeutics LLC, Los Altos, California, USA.
  • Darpo B; ERT, Inc. (previously iCardiac Technologies), Rochester, New York, USA.
  • Chen C; Takeda Pharmaceuticals International Co., Cambridge, Massachusetts, USA.
  • Fletcher M; MedAssessment, Inc., San Clemente, California, USA.
  • Combs D; Combs Consulting Service, Mountain View, California, USA.
  • Xue H; ERT, Inc. (previously iCardiac Technologies), Rochester, New York, USA.
  • Stoltz RR; Covance Laboratories Inc., Clinical Research Unit, Evansville, Indiana, USA.
Clin Pharmacol Drug Dev ; 10(8): 927-939, 2021 08.
Article em En | MEDLINE | ID: mdl-33462988
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Prolactina / Triazóis / Jejum Tipo de estudo: Clinical_trials Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Prolactina / Triazóis / Jejum Tipo de estudo: Clinical_trials Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article